Immune-related saliva micro-RNA’s to predict clinical response to a combination of cetuximab and low-dose chemotherapy in head and neck cancer (HNSCC) patients (pts) with poor performance status (PS).
CARPINTERIA, Calif.--(BUSINESS WIRE)--InHealth Technologies, maker of Blom-Singer® voice restoration and ENT products and a business unit of Freudenberg Medical, announces the commercial launch of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results